PNC-27

59,99 

FOR PRECLINICAL RESEARCH USE ONLY — NOT APPROVED FOR HUMAN USE.
  • Selective destruction of cancer cells without harming normal cells.
  • Activity against breast, ovarian, cervical, and pancreatic cancer cell lines.
  • A novel mechanism that differs from conventional chemotherapy.
  • Potential to circumvent resistance mechanisms.
SKU: SELMPNC27 Category: Healing & Tissue Repair Tag:
Description
PNC-27
Cancer Research

MECHANISM OF ACTION

A 32-residue chimeric p53-penetratin peptide. HDM-2-binding domain, residues 12–26 of p53, fused to a cell-penetrating penetratin sequence. It selectively binds to HDM-2 overexpressed on cancer cell membranes—which is not expressed on normal cell surfaces—promoting the formation of pores in the membrane and the selective necrosis of tumor cells.

KEY BENEFITS

  • Selective destruction of cancer cells without harming normal cells.
  • Activity against breast, ovarian, cervical, and pancreatic cancer cell lines.
  • A novel mechanism that differs from conventional chemotherapy.
  • Potential to circumvent resistance mechanisms.

SIDE EFFECTS AND SAFETY

Currently in the research phase only. There is no established human safety profile.

RESEARCH AND CLINICAL NOTES

Bowne et al. (2008): PNC-27 destroyed 100% of breast cancer cells and more than 99% of pancreatic cancer cells in vitro within 1 hour. Selectivity confirmed for tumor cells expressing HDM-2. Phase I in the planning stage.

TARGET PROFILE:

Research protocols focused on oncology and complementary integrative oncology programs.

Additional information
Weight,26 kg